Target Binding Site Detail
Target General Information | Top | ||||
---|---|---|---|---|---|
Target ID | T13726 | Target Info | |||
Target Name | Retinoic acid receptor RXR-alpha (RXRA) | ||||
Synonyms | Retinoid X receptor alpha; RXRalpha; Nuclear receptor subfamily 2 group B member 1; NR2B1 | ||||
Target Type | Successful Target | ||||
Gene Name | RXRA | ||||
Biochemical Class | Nuclear hormone receptor | ||||
UniProt ID |
Ligand General Information | Top | ||||
---|---|---|---|---|---|
Ligand Name | Tretinoin | Ligand Info | |||
Canonical SMILES | CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC(=O)O)C)C | ||||
InChI | 1S/C20H28O2/c1-15(8-6-9-16(2)14-19(21)22)11-12-18-17(3)10-7-13-20(18,4)5/h6,8-9,11-12,14H,7,10,13H2,1-5H3,(H,21,22)/b9-6+,12-11+,15-8+,16-14+ | ||||
InChIKey | SHGAZHPCJJPHSC-YCNIQYBTSA-N | ||||
PubChem Compound ID | 444795 |
Drug Binding Sites of Target | Top | |||||
---|---|---|---|---|---|---|
PDB ID: 3FC6 hRXRalpha & mLXRalpha with an indole Pharmacophore, SB786875 | ||||||
Method | X-ray diffraction | Resolution | 2.06 Å | Mutation | No | [1] |
PDB Sequence |
SANEDMPVER
234 ILEAELAVDP264 VTNICQAADK274 QLFTLVEWAK284 RIPHFSELPL294 DDQVILLRAG 304 WNELLIASFS314 HRSIAVKDGI324 LLATGLHVHR334 NSAHSAGVGA344 IFDRVLTELV 354 SKMRDMQMDK364 TELGCLRAIV374 LFNPDSKGLS384 NPAEVEALRE394 KVYASLEAYC 404 KHKYPEQPGR414 FAKLLLRLPA424 LRSIGLKCLE434 HLFFFKLDTF450 LMEMLEA |
|||||
|
VAL265
4.398
ILE268
3.809
CYS269
4.244
ALA271
3.388
ALA272
3.270
GLN275
3.608
TRP305
3.746
ASN306
4.622
LEU309
4.030
ILE310
4.172
|
|||||
PDB ID: 3FAL humanRXR alpha & mouse LXR alpha complexed with Retenoic acid and GSK2186 | ||||||
Method | X-ray diffraction | Resolution | 2.36 Å | Mutation | No | [2] |
PDB Sequence |
NEDMPVERIL
236 EAELAVDPVT266 NICQAADKQL276 FTLVEWAKRI286 PHFSELPLDD296 QVILLRAGWN 306 ELLIASFSHR316 SIAVKDGILL326 ATGLHVHRNS336 AHSAGVGAIF346 DRVLTELVSK 356 MRDMQMDKTE366 LGCLRAIVLF376 NPDSKGLSNP386 AEVEALREKV396 YASLEAYCKH 406 KYPEQPGRFA416 KLLLRLPALR426 SIGLKCLTFL452 MEMLEA
|
|||||
|
||||||
PDB ID: 2ACL Liver X-Receptor alpha Ligand Binding Domain with SB313987 | ||||||
Method | X-ray diffraction | Resolution | 2.80 Å | Mutation | Yes | [3] |
PDB Sequence |
SANEDMPVER
234 ILEAELAVED263 PVTNICQAAD273 KQLFTLVEWA283 KRIPHFSELP293 LDDQVILLRA 303 GWNELLIASF313 SHRSIAVKDG323 ILLATGLHVH333 RNSAHSAGVG343 AIFDRVLTEL 353 VSKMRDMQMD363 KTELGCLRAI373 VLFNPDSKGL383 SNPAEVEALR393 EKVYASLEAY 403 CKHKYPEQPG413 RFAKLLLRLP423 ALRSIGLKCL433 EHLFFFKLIG443 DTPIDTFLME 453 MLEA
|
|||||
|
VAL265
4.386
ILE268
3.913
CYS269
4.422
ALA271
3.523
ALA272
3.474
GLN275
3.246
TRP305
4.184
ASN306
3.749
LEU309
3.812
ILE310
4.137
|
References | Top | ||||
---|---|---|---|---|---|
REF 1 | Synthesis and SAR of potent LXR agonists containing an indole pharmacophore. Bioorg Med Chem Lett. 2009 Feb 15;19(4):1097-100. | ||||
REF 2 | Structure-guided design of N-phenyl tertiary amines as transrepression-selective liver X receptor modulators with anti-inflammatory activity. J Med Chem. 2008 Sep 25;51(18):5758-65. | ||||
REF 3 | Discovery of substituted maleimides as liver X receptor agonists and determination of a ligand-bound crystal structure. J Med Chem. 2005 Aug 25;48(17):5419-22. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.